DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- Other: No drug
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 800
- Registration Number
- NCT06585501
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, China
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 700
- Registration Number
- NCT06578247
- Locations
- 🇺🇸
City of Hope Phoenix, Goodyear, Arizona, United States
🇺🇸Mayo Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
- Conditions
- Non-small Cell Lung CancerMetastatic CancerLung CancerBrain and Central Nervous System Cancer
- Interventions
- Other: No drug
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 22517
- Registration Number
- NCT06557967
- Locations
- 🇺🇸
ConcertAI Database, Cambridge, Massachusetts, United States
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
- Conditions
- Neuropathic PainChemotherapy-induced Peripheral NeuropathyDiabetic Peripheral Neuropathic Pain
- Interventions
- Other: No Drug
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1000
- Registration Number
- NCT06546202
- Locations
- 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian City, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 123
- Registration Number
- NCT06362252
- Locations
- 🇺🇸
Advent Health Orlando, Orlando, Florida, United States
🇺🇸University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 520
- Registration Number
- NCT06330064
- Locations
- 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Pih Health Hematology Medical Oncology, Whittier, California, United States
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
- Conditions
- EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT06279728
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸Graves Gilbert Clinic, Bowling Green, Kentucky, United States
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Daiichi Sankyo Inc.
- Target Recruit Count
- 45
- Registration Number
- 2024-516916-93-00
- Locations
- 🇫🇷
Oncopole Claudius Regaud, Toulouse Cedex 9, France
🇫🇷Centre Hospitalier Universitaire De Poitiers, Poitiers, France
🇫🇷Institut De Cancerologie De L Ouest, Saint-Herblain Cedex, France
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Conditions
- HER2-positive Breast CancerHER2-low Breast CancerBreast CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 800
- Registration Number
- NCT06210776
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳Peking University First Hospital, Beijing, China
🇨🇳The Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Daiichi Sankyo Inc.
- Target Recruit Count
- 212
- Registration Number
- 2023-509628-16-00
- Locations
- 🇩🇪
Justus-Liebig-Universitaet Giessen, Giessen, Germany
🇩🇪Goethe University Frankfurt, Frankfurt Am Main, Germany
🇩🇪Universitaetsklinikum Ulm AöR, Ulm, Germany